Ethambutol
- Generic Name
- Ethambutol
- Brand Names
- Etibi, Myambutol
- Drug Type
- Small Molecule
- Chemical Formula
- C10H24N2O2
- CAS Number
- 74-55-5
- Unique Ingredient Identifier
- 8G167061QZ
- Background
Ethambutol is a bacteriostatic agent indicated alongside medications such as isoniazid, rifampin, and pyrazinamide in the treatment of pulmonary tuberculosis. Ethambutol was first described in the literature in 1961. It was developed out of a need for therapies active against isoniazid resistant strains of Mycobacterium tuberculosis.
...
- Indication
Ethambutol is indicated in combination with other anti-tuberculosis drugs in the treatment of pulmonary tuberculosis. Ethambutol is commonly used in combination with isoniazid, rifampin, and pyrazinamide.
- Associated Conditions
- Mycobacterium Avium Intracellulare Complex (MAC), Mycobacterium Infections, Pulmonary Tuberculosis (TB)
- Associated Therapies
- -
Validation of Patient Reported Outcome Measures in Participants With Nontuberculous Mycobacterial Lung Infection Caused by Mycobacterium Avium Complex
- Conditions
- Interventions
- First Posted Date
- 2020-12-21
- Last Posted Date
- 2024-06-28
- Lead Sponsor
- Insmed Incorporated
- Target Recruit Count
- 99
- Registration Number
- NCT04677543
- Locations
- 🇪🇸
ESP002, Barcelona, Spain
🇪🇸ESP004, Madrid, Spain
🇪🇸ESP003, Barcelona, Spain
Study to Evaluate ALIS (Amikacin Liposome Inhalation Suspension) in Participants With Nontuberculous Mycobacterial Lung Infection Caused by Mycobacterium Avium Complex
- Conditions
- Interventions
- First Posted Date
- 2020-12-21
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- Insmed Incorporated
- Target Recruit Count
- 425
- Registration Number
- NCT04677569
- Locations
- 🇺🇸
USA014, Saint Petersburg, Florida, United States
🇺🇸USA084, Sebastian, Florida, United States
🇺🇸USA067, Tampa, Florida, United States
A Study of Bedaquiline Administered as Part of a Treatment Regimen With Clarithromycin and Ethambutol in Adult Patients With Treatment-refractory Mycobacterium Avium Complex-lung Disease (MAC-LD)
- Conditions
- Interventions
- First Posted Date
- 2020-11-16
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Janssen Pharmaceutical K.K.
- Target Recruit Count
- 129
- Registration Number
- NCT04630145
- Locations
- 🇰🇷
Chonnam National University Hospital, Gwangju, Korea, Republic of
🇯🇵St. Luke's International Hospital, Chuo ku, Japan
🇯🇵Fukui Prefectural Hospital, Fukui-shi, Japan
Rosuvastatin Evaluation as a Tuberculosis Treatment Adjunct
- Conditions
- Interventions
- First Posted Date
- 2020-08-07
- Last Posted Date
- 2020-08-07
- Lead Sponsor
- National University Hospital, Singapore
- Target Recruit Count
- 154
- Registration Number
- NCT04504851
- Locations
- 🇺🇬
Joint Clinical Research Centre, Kampala, Uganda
🇻🇳Vietnam Military Medical University, Hanoi, Vietnam
🇵🇭Tropical Disease Foundation, Makati City, Philippines
Treatment Shortening of Drug-Sensitive Pulmonary Tuberculosis Using High Dose Rifampicin (Hi-DoRi-3)
- Conditions
- Interventions
- First Posted Date
- 2020-07-24
- Last Posted Date
- 2020-07-24
- Lead Sponsor
- Seoul National University Hospital
- Target Recruit Count
- 926
- Registration Number
- NCT04485156
- Locations
- 🇰🇷
Division of Pulmonology and Critical Care Medicine, Department of Internal Medicine and Lung Institute of Medical Research Center, Seoul National University College of Medicine, Seoul, Korea, Republic of
Finding the Optimal Regimen for Mycobacterium Abscessus Treatment
- Conditions
- Interventions
- First Posted Date
- 2020-03-17
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- The University of Queensland
- Target Recruit Count
- 300
- Registration Number
- NCT04310930
- Locations
- 🇦🇺
St George Hospital, Kogarah, New South Wales, Australia
🇦🇺Austin Hospital, Heidelberg, Victoria, Australia
🇦🇺Royal Melbourne Hospital, Parkville, Victoria, Australia
Efficacy and Safety of Intravenous Treatment of Tuberculosis
- Conditions
- Interventions
- First Posted Date
- 2019-11-04
- Last Posted Date
- 2019-11-07
- Lead Sponsor
- Yuria-Pharm
- Target Recruit Count
- 166
- Registration Number
- NCT04150367
- Locations
- 🇺🇦
Regional Antituberculosis Dispensary, Kherson, Ukraine
🇺🇦Regional Clinical Antituberculosis Dispensary, Sumy, Ukraine
🇺🇦Regional phthisiopulmonary center, Ivano-Frankivs'k, Ukraine
Multicenter, Randomized Study Evaluating the Value of Antitubercular Treatment During Recurent Anterior Uveitis (URBA)
- Conditions
- Interventions
- First Posted Date
- 2019-10-07
- Last Posted Date
- 2019-10-07
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Target Recruit Count
- 116
- Registration Number
- NCT04117698
Comparison of Two- Versus Three-antibiotic Therapy for Pulmonary Mycobacterium Avium Complex Disease
- Conditions
- Interventions
- First Posted Date
- 2018-09-14
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Kevin Winthrop
- Target Recruit Count
- 474
- Registration Number
- NCT03672630
- Locations
- 🇺🇸
Loma Linda University Medical Center, Loma Linda, California, United States
🇺🇸University of California, San Diego, San Diego, California, United States
🇺🇸University of California, San Francisco, San Francisco, California, United States
Two-month Regimens Using Novel Combinations to Augment Treatment Effectiveness for Drug-sensitive Tuberculosis
- First Posted Date
- 2018-03-22
- Last Posted Date
- 2023-08-14
- Lead Sponsor
- University College, London
- Target Recruit Count
- 675
- Registration Number
- NCT03474198
- Locations
- 🇮🇩
Saiful Anwar Hospital, Malang, Indonesia
🇺🇬Joint Clinical Research Centre, Mbarara, Uganda
🇺🇬Infectious Diseases Institute, Kampala, Uganda
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.